EpiEndo Pharmaceuticals Secures EUR 20 Million Series a Funding to Advance Clinical Development of Its Non-antibiotic Macrolide for the Treatment of COPD

EpiEndo Pharmaceuticals, Inc. announced the closing of a €20m Series A financing round led by Flerie Invest and Iðunn Venture Fund, with existing investors ABC Ventures participating, along with the European Innovation Council (EIC) Fund joining the round. The financing secures funds to advance clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication.